Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.

被引：0
|
作者：
Ni, Jun
Zhang, Xiaotong
Pan, Ruili
Wang, Hanping
Si, Xiaoyan
Cui, Xiaoxia
Zhang, Li
机构：
[1] Chinese Acad Med Sci Peking Union Med Coll, Peking Union Med Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China
[2] Peking Union Med Coll & Chinese Acad Med Sci, Dept Pulm & Crit Care Med, Peking Union Med Coll Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Dept Resp Med, Peking Union Med Coll Hosp, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China
[5] Peking Union Med Coll & Chinese Acad Med Sci, Dept Pulm & Crit Care Med, Peking Union Med Coll Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8573
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study.
    Zhao, Yanbin
    Zhang, Minghui
    Liu, Jinglei
    Pu, Haihong
    Li, Yinghong
    Li, Xin
    Wang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction
    Peng, Zhi
    Wei, Jia
    Wang, Feng
    Ying, Jieer
    Deng, Yanhong
    Gu, Kangsheng
    Cheng, Ying
    Yuan, Xianglin
    Xiao, Juxiang
    Tai, Yanfei
    Wang, Linna
    Zou, Jianjun
    Zhang, Yanqiao
    Shen, Lin
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3069 - 3078
  • [3] Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study
    Liu, Wenlou
    Wang, Hongmei
    Zhao, Yang
    Ge, Yan
    Tang, Juangjuang
    Cao, Menghan
    Matsas, Silvio
    Breadner, Daniel Adam
    Qin, Xiaobing
    Han, Zhengxiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04)
  • [4] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [5] Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer
    Zhang, Dou
    Kong, Fanming
    Gao, Fangfang
    Li, Longhui
    Liang, Yangyueying
    Yu, Minghui
    Zhao, Lu
    Wang, Na
    Jia, Yingjie
    HELIYON, 2024, 10 (01)
  • [6] A phase II study to evaluate the safety and efficacy of radiotherapy combined with irinotecan liposome followed by camrelizumab and apatinib for advanced solid tumors that failed standard treatments
    Shen, Jie
    Li, Rutian
    Yan, Jing
    Du, Juan
    Wei, Jia
    Zhu, Sihui
    Liu, Ying
    Li, Huajun
    Liu, Baorui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Efficacy and safety of SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous cell carcinoma: A phase II study.
    Wang, Jinliang
    Zhang, Zhibo
    Yan, Xiang
    Ma, Junxun
    Zhang, Fan
    Song, Qi
    Zhang, Li
    Liu, Zhefeng
    Yang, Bo
    Wang, Lijie
    Tao, Haitao
    Zhang, Sujie
    Li, Xiaoyan
    Hu, Jie
    Li, Xiaoting
    Wang, Jiaqian
    Zhi, Xiaoyu
    Ge, Xiangwei
    Jiao, Shunchang
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
    Zhao, Y.
    Liu, J.
    Li, X.
    Li, Y.
    Pu, H.
    Wang, X.
    Yang, M.
    Bai, S.
    Guo, L.
    Zhao, L.
    Zhang, M.
    Zhao, H.
    Xu, S.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1674 - S1674
  • [9] Efficacy and safety of camrelizumab combined with apatinib in the treatment of advanced gastric cancer: Preliminary results from a multicenter, prospective study.
    He, Yifu
    Hu, Bing
    Liu, Ke
    Cheng, Xiaofei
    Cheng, Huaidong
    Chen, Mo
    Hu, Changlu
    Li, Chenghui
    Mei, Xinkuan
    Liu, Jianfeng
    Liu, Hu
    Wang, Gang
    Li, Hongxia
    Zhang, Dingqing
    Luo, Huiqin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Camrelizumab combined with apatinib and albumin-bound paclitaxel followed by camrelizumab plus apatinib as first-line therapy for unresectable or metastatic pancreatic cancer.
    Shen, Bo
    Wu, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 703 - 703
12345